Pasithea Therapeutics Corp.
KTTA
$1.17
-$0.03-2.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.75M | 1.66M | 1.95M | 1.75M | 1.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -19.50K | -- | -- | -- |
| Total Operating Expenses | 3.11M | 3.79M | 3.68M | 3.26M | 3.00M |
| Operating Income | -3.11M | -3.79M | -3.68M | -3.26M | -3.00M |
| Income Before Tax | -3.04M | -3.72M | -3.56M | -3.18M | -3.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.04M | -3.72M | -3.56M | -3.18M | -3.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.04M | -3.72M | -3.56M | -3.18M | -3.00M |
| EBIT | -3.11M | -3.79M | -3.68M | -3.26M | -3.00M |
| EBITDA | -2.93M | -3.63M | -3.52M | -3.10M | -2.84M |
| EPS Basic | -0.41 | -0.66 | -1.61 | -2.53 | -2.87 |
| Normalized Basic EPS | -0.26 | -0.41 | -1.01 | -1.58 | -1.80 |
| EPS Diluted | -0.41 | -0.66 | -1.61 | -2.53 | -2.87 |
| Normalized Diluted EPS | -0.26 | -0.41 | -1.01 | -1.58 | -1.80 |
| Average Basic Shares Outstanding | 7.44M | 5.64M | 2.21M | 1.25M | 1.04M |
| Average Diluted Shares Outstanding | 7.44M | 5.64M | 2.21M | 1.25M | 1.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |